Shannon Meeks

SOM: Peds: HemThrom
Professor

Aflac Cancer and Blood Disorders Center
Pediatrics
2015 Uppergate Drive

Academic Appointment

Professor of Pediatrics, Emory University

Education

Degrees

BS from Duke University
MD from University of Mississippi School of Medicine

Research

Focus

a. The immune response to infusion of factor VIII in a murine hemophilia A model b. B cell epitope mapping in hemophilia A patients

Publications

Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production.
J Thromb Haemost Volume: 23 Page(s): 440 - 457
02/01/2025 Authors: York ES; Dratch BD; Ito J; Horwitz SM; Emamian S; Ambarian JA; Gill S; Jones J; Chonat S; Lollar P
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.
Haemophilia Volume: 31 Page(s): 78 - 86
01/01/2025 Authors: Dunn A; Dargaud Y; Abajas Y; Carcao M; Castaman G; Giermasz A; Hermans C; Jimnez-Yuste V; Lewandowska M; Mahlangu J
Marginal Zone B Cells Represent a Conserved Initiating Player in the Immune Response to Factor VIII in Hemophilia A Mice.
Thromb Haemost Volume: 124 Page(s): 893 - 896
09/01/2024 Authors: Maarouf M; Patel SR; Baldwin WH; Zerra PE; Cox C; Parker ET; Stowell SR; Meeks SL
Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size.
J Thromb Haemost Volume: 22 Page(s): 2052 - 2058
07/01/2024 Authors: Liang Q; Parker ET; Dean G; Karpen MS; Wu Y; Wang X; Di Paola J; Maier CL; Meeks SL; Lollar P
Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
Haemophilia Volume: 30 Suppl 3 Page(s): 95 - 102
04/01/2024 Authors: Meeks SL; Zimowski KL
Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses.
Ther Adv Hematol Volume: 15 Page(s): 20406207241300809
01/01/2024 Authors: Knigs C; Meeks SL; Nolan B; Schmidt A; Lfqvist M; Dumont J; Leickt L; Nayak S; Lethagen S
Stigma, social and structural vulnerability, and mental health among transgender women: A partial least square path modeling analysis.
J Nurs Scholarsh Volume: 56 Page(s): 42 - 59
01/01/2024 Authors: Sherman ADF; Higgins MK; Balthazar MS; Hill M; Klepper M; Schneider JS; Adams D; Radix A; Mayer KH; Cooney EE
Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients.
J Clin Med Volume: 12
03/06/2023 Authors: Reipert BM; Hofbauer CJ; Gangadharan B; Berg V; Donnachie E; Meeks S; Mancuso ME; Bowen J; Brown DL
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia.
Expert Rev Hematol Volume: 16 Page(s): 19 - 37
03/01/2023 Authors: Tran DQ; Benson CC; Boice JA; Chitlur M; Dunn AL; Escobar MA; Gupta K; Johnsen JM; Jorgenson J; Martin SD
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner.
Front Immunol Volume: 14 Page(s): 1233356
01/01/2023 Authors: Batsuli G; Ito J; York ES; Cox C; Baldwin W; Gill S; Lollar P; Meeks SL
Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity.
Biomedicines Volume: 10
07/18/2022 Authors: Zerra PE; Parker ET; Baldwin WH; Healey JF; Patel SR; McCoy JW; Cox C; Stowell SR; Meeks SL
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Haemophilia Volume: 28 Page(s): 548 - 556
07/01/2022 Authors: Pipe SW; Hermans C; Chitlur M; Carcao M; Castaman G; Davis JA; Ducore J; Dunn AL; Escobar M; Journeycake J
INTRODUCING A BIOPHYSICAL PLATELET FUNCTION PANEL TO INVESTIGATE BLEEDING OF UNKNOWN CAUSE
Volume: 69
06/01/2022 Authors: Azer S; Oshinowo O; Fay M; Sakurai Y; Qiu Y; Bennett C; Meeks S; Brown M; Myers D; Lam W
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
Res Pract Thromb Haemost Volume: 6 Page(s): e12731
05/01/2022 Authors: Ngrier C; Oldenburg J; Kenet G; Meeks SL; Bordet J-C; Mller J; Le Quellec S; Turecek PL; Tripkovic N; Dargaud Y
Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China.
Haemophilia Volume: 28 Suppl 4 Page(s): 111 - 118
05/01/2022 Authors: Escuriola Ettingshausen C; Yang R; Wu W; Meeks SL
Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
Blood Volume: 139 Page(s): 1312 - 1317
03/03/2022 Authors: Arthur CM; Zerra PE; Shin S; Wang J; Song X; Doering CB; Lollar P; Meeks S; Stowell SR
Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
J Cardiothorac Vasc Anesth Volume: 36 Page(s): 724 - 727
03/01/2022 Authors: Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway.
Front Immunol Volume: 13 Page(s): 880829
01/01/2022 Authors: Patel SR; Lundgren TS; Baldwin WH; Cox C; Parker ET; Healey JF; Jajosky RP; Zerra PE; Josephson CD; Doering CB
B cell-activating factor modulates the factor VIII immune response in hemophilia A.
J Clin Invest Volume: 131
04/15/2021 Authors: Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status.
Res Pract Thromb Haemost Volume: 5 Page(s): 342 - 348
02/01/2021 Authors: Batsuli G; Greene A; Meeks SL; Sidonio RF
Discordance between platelet-supported and vesicle-supported factor VIII activity in the presence of anti-C2 domain inhibitory antibodies.
J Thromb Haemost Volume: 18 Page(s): 3184 - 3193
12/01/2020 Authors: Chatterjee M; Meeks S; Novakovic VA; Gilbert GE
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.
Blood Adv Volume: 4 Page(s): 5785 - 5796
11/24/2020 Authors: Reipert BM; Gangadharan B; Hofbauer CJ; Berg V; Schweiger H; Bowen J; Blatny J; Fijnvandraat K; Mullins ES; Klintman J
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.
Haemophilia Volume: 26 Page(s): 958 - 965
11/01/2020 Authors: Meeks SL; Lacroix-Desmazes S
Inhibitor status of patients with Hemophilia A who transition to Emicizumab after Immune Tolerance Induction
Volume: 26 Page(s): 28 - 28
06/01/2020 Authors: Batsuli G; Greene A; Meeks SL; Sidonio RF
THE IMPACT OF CONCURRENT X-CHROMOSOME ABNORMALITIES ON BLEEDING PHENOTYPE IN PEDIATRIC HEMOPHILIA
Volume: 67 Page(s): S61 - S61
06/01/2020 Authors: Soffer E; Coleman K; Meeks S; Batsuli G
Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.
Front Immunol Volume: 11 Page(s): 905
01/01/2020 Authors: Zerra PE; Arthur CM; Chonat S; Maier CL; Mener A; Shin S; Allen JWL; Baldwin WH; Cox C; Verkerke H
Development and application of global assays of hyper- and hypofibrinolysis.
Res Pract Thromb Haemost Volume: 4 Page(s): 46 - 53
01/01/2020 Authors: Ilich A; Noubouossie DF; Henderson M; Ellsworth P; Betbadal KF; Campello E; Meeks S; Dunn A; Park MS; Pawlinski R
The Immune Response to Murine Factor VIII in Single Exon Deletion and Total Gene Deletion Murine Models of Hemophilia a
Volume: 134
11/13/2019 Authors: Patel SR; Baldwin WH; Cox C; Healey J; Parker ET; Batsuli G; Meeks SL
Severe Bleeding Events in Hemophilia. Patients Receiving Emicizumab Prophylaxis
Volume: 134
11/13/2019 Authors: Zimowski KL; Batsuli GM; Bryant P; McDaniel J; Tickle K; Meeks SL; Sidonio RF
Epitope Dependent Augmentation of the Immune Response in Hemophilia. Mice Immunized with Factor VIII/Antibody Immune Complexes
Volume: 134
11/13/2019 Authors: Batsuli G; Patel SR; Cox C; Baldwin WH; Lollar JS; Meeks SL
The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors.
Haemophilia Volume: 25 Page(s): 911 - 918
11/01/2019 Authors: Meeks SL; Leissinger CA
BASELINE PATIENT CHARACTERISTICS IN REITIRATE - A PROSPECTIVE STUDY OF RESCUE ITI WITH RECOMBINANT FACTOR VIIIFC (RFVIIIFC) IN PATIENTS WHO HAVE FAILED PREVIOUS ITI ATTEMPTS
Volume: 104 Page(s): 15 - 15
09/09/2019 Authors: Koenigs C; Meeks SL; Malmstrom H; Jain N; Lethagen S
COMBINATION OF EMICIZUMAB WITH SIM OCT OCOG ALFA FOR PROPHYLAXIS IN PREVIOUSLY UNTREATED/MINIMALLY TREATED HEMOPHILIA A PATIENTS, AND FOR MANAGING INHIBITOR PATIENTS
Volume: 104 Page(s): 16 - 17
09/09/2019 Authors: Sidonio R; Meeks SL; Shapiro A; Manco-Johnson M; Callaghan M
MOTIVATE: MODERN TREATMENT OF INHIBITOR-POSITIVE PATIENTS WITH HEMOPHILIA A - AN INTERNATIONAL OBSERVATIONAL STUDY
Volume: 104 Page(s): 20 - 20
09/09/2019 Authors: Escuriola-Ettinghausen C; Sidonio RF; Oldenburg J; Pezeshkpoor B; Mueller J; Konkle BA; Meeks SL; Dargaud Y; Pavlova A; Young G
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
Haemophilia Volume: 25 Page(s): 789 - 796
09/01/2019 Authors: Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
Tracking the immune response to factor VIII in hemophilia A
Volume: 25 Page(s): 53 - 53
07/01/2019 Authors: Patel S; Baldwin W; Stowell S; Meeks S
FVIII-specific CD4 T cell proliferation requires multiple previous exposures to FVIII
Volume: 25 Page(s): 76 - 76
07/01/2019 Authors: Zerra P; Patel S; Baldwin W; Healey J; Parker E; Cox C; Lollar P; Stowell S; Meeks S
The national blueprint for future basic and translational research to understand factor VIII immunogenicity: NHLBI State of the Science Workshop on factor VIII inhibitors.
Haemophilia Volume: 25 Page(s): 595 - 602
07/01/2019 Authors: Meeks SL; Herzog RW; Members of Working Group 3, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research
Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice.
Blood Adv Volume: 3 Page(s): 288 - 300
02/12/2019 Authors: Weitzmann MN; Roser-Page S; Vikulina T; Weiss D; Hao L; Baldwin WH; Yu K; Del Mazo Arbona N; McGee-Lawrence ME; Meeks SL
Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks
Volume: 25 Page(s): 45 - 46
02/01/2019 Authors: Kiialainen A; Schmitt C; Adamkewicz JI; Petry C; Pipe S; Young G; Mahlangu J; Lehle M; Chang T; Dhalluin C
Factor XIII, alpha(2)-Antiplasmin, and Plasminogen Activator Inhibitor-1 Deficiencies
Page(s): 707 - 710
01/01/2019 Authors: Batsuli G; Meeks SL
Congenital Disorders of Fibrinogen
Page(s): 703 - 706
01/01/2019 Authors: Batsuli G; Meeks SL
Factor II, Factor V, and Factor X Deficiencies
Page(s): 699 - 702
01/01/2019 Authors: Zimowski KL; Meeks SL
Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis
Volume: 132
11/29/2018 Authors: Zimowski KL; Batsuli GM; Reding MT; Rana J; Callaghan MU; Tickle K; Meeks SL; Sidonio RF
Anti-C1 domain antibodies that accelerate factorVIII clearance contribute to antibody pathogenicity in a murine hemophiliaA model.
J Thromb Haemost Volume: 16 Page(s): 1779 - 1788
09/01/2018 Authors: Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
ETHICAL DECISION MAKING FRAMEWORK IN PREVIOUSLY UNTREATED SEVERE HEMOPHILIA A PATIENTS
Volume: 65
06/01/2018 Authors: Lanzel AF; Soucie JM; Ortmann L; Barrett D; Sidonio R; Meeks S
Effect of combination plasma derived and recombinant factor VIII on infusion volumes in children hemophilia A with and without inhibitors: an update of a single institution experience
Volume: 24 Page(s): 87 - 87
05/01/2018 Authors: Meeks S
Long-term outcomes of patients with severe hemophilia A and high titer inhibitors with partial tolerance after immune tolerance induction
Volume: 24 Page(s): 48 - 49
05/01/2018 Authors: Batsuli G; Meeks S; Sidonio R
Utilization of a virtual reality based tool in hemophilia education
Volume: 24 Page(s): 132 - 133
05/01/2018 Authors: Dunn A; Meeks S; Patterson J; Luna J; Stanek J; Kruse-Jarres R; Kaur D
A microengineered vascularized bleeding model that integrates the principal components of hemostasis.
Nat Commun Volume: 9 Page(s): 509
02/06/2018 Authors: Sakurai Y; Hardy ET; Ahn B; Tran R; Fay ME; Ciciliano JC; Mannino RG; Myers DR; Qiu Y; Carden MA
The Impact of Anti-Factor VIII A1 and A3 Domain Antibodies in the Immune Reponse to Factor VIII in Patients with Hemophilia a
Volume: 130
12/07/2017 Authors: Ito JC; Cox C; Baldwin WH; Doering CB; Meeks SL
The Impact of Specific Factor VIII Domains on Uptake By Dendritic Cells
Volume: 130
12/07/2017 Authors: Batsuli GM; Meeks SL; Lollar JS
Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
Blood Volume: 130 Page(s): 2559 - 2568
12/07/2017 Authors: Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
Platelet-Microcapsule Hybrids Leverage Contractile Force for Targeted Delivery of Hemostatic Agents.
ACS Nano Volume: 11 Page(s): 5579 - 5589
06/27/2017 Authors: Hansen CE; Myers DR; Baldwin WH; Sakurai Y; Meeks SL; Lyon LA; Lam WA
Thrombin Generation in Patients with Severe Hemophilia A is Variable and May be Predictive of Response to Treatment
Volume: 64 Page(s): S15 - S15
06/01/2017 Authors: Sharma R; Dunn A; Jobe S; Meeks S
Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction.
Nat Biotechnol Volume: 35 Page(s): 35 - 37
01/01/2017 Authors: Zakas PM; Brown HC; Knight K; Meeks SL; Spencer HT; Gaucher EA; Doering CB
Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.
Hematology Am Soc Hematol Educ Program Volume: 2016 Page(s): 657 - 662
12/02/2016 Authors: Meeks SL; Batsuli G
Leveraging the Contractile Force of Platelets for Targeted Factor VIII Delivery in Hemophilia with Inhibitors
Volume: 128
12/02/2016 Authors: Hansen CE; Myers DR; Sakurai Y; Baldwin WH; Meeks SL; Lyon LA; Lam WA
Factor VIII C2 Domain Epitopes Recognized By Classical and Non-Classical Anti-C2 Domain Monoclonal Antibodies Help Mediate FVIII Uptake By Dendritic Cells
Volume: 128
12/02/2016 Authors: Batsuli G; Baldwin WH; Healey JF; Parker ET; Cox C; Lollar P; Meeks SL
Very High Dose Factor VIII Needed to Prevent Bleeding in the Presence of a Low Titer Anti-C1 Domain Antibody
Volume: 128
12/02/2016 Authors: Ito J; Mercer R; Baldwin WH; Batsuli G; Meeks SL
High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Blood Volume: 128 Page(s): 2055 - 2067
10/20/2016 Authors: Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Knigs C; Li R
Innovating immune tolerance induction for haemophilia.
Haemophilia Volume: 22 Suppl 5 Page(s): 31 - 35
07/01/2016 Authors: Batsuli G; Meeks SL; Herzog RW; Lacroix-Desmazes S
Thrombin generation does not correlate with disease severity but may be predictive of response to treatment in patients with severe hemophilia A
JOURNAL OF THROMBOSIS AND HAEMOSTASIS Volume: 14 Page(s): 53 - 53
05/01/2016 Authors: Sharma R; Dunn A; Jobe S; Meeks S
A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.
Blood Volume: 127 Page(s): 2028 - 2034
04/21/2016 Authors: Eubanks J; Baldwin WH; Markovitz R; Parker ET; Cox C; Kempton CL; Meeks SL
Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
J Thromb Haemost Volume: 14 Page(s): 346 - 355
02/01/2016 Authors: Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL
B-Cell Epitope Mapping of Severe Hemophilia a Plasma Using Well Characterized Murine Anti-Factor VIII Monoclonal Antibodies
Volume: 126
12/03/2015 Authors: Meeks S; Baldwin WH; Cox C
Anti-C1 Domain Antibodies Are Pathogenic in a Murine Tail Snip Model Despite Low Inhibitor Titers
Volume: 126
12/03/2015 Authors: Batsuli G; Healey J; Parker E; Baldwin WH; Nguyen B; Lollar P; Meeks SL
Marginal Zone B Cell Depletion Prevents Factor VIII Inhibitor Development in Model of Hemophilia
Volume: 126
12/03/2015 Authors: Cox C; Zerra P; Authur C; Patel S; Meeks S; Stowell SR
One-Stage FVIII Activity Is Inversely Correlated with Heavy Menstrual Bleeding in Hemophilia a Carriers
Volume: 126
12/03/2015 Authors: Sidonio RF; Meeks SL; Whitworth HB
Engineering a Valve-Regulated Endothelialized Microfluidic Device As an "in Vitro" Bleeding Time for Assessing Global Hemostasis
Volume: 126
12/03/2015 Authors: Sakurai Y; Hardy ET; Ahn B; Meeks SL; Baldwin WH; Jobe SM; Lam WA
US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.
Haemophilia Volume: 21 Page(s): 559 - 567
09/01/2015 Authors: Valentino LA; Kempton CL; Kruse-Jarres R; Mathew P; Meeks SL; Reiss UM; International Immune Tolerance Induction Study Investigators
Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach.
Blood Volume: 126 Page(s): 817 - 824
08/06/2015 Authors: Ciciliano JC; Sakurai Y; Myers DR; Fay ME; Hechler B; Meeks S; Li R; Dixon JB; Lyon LA; Gachet C
The immunogenicity of factor VIII
JOURNAL OF THROMBOSIS AND HAEMOSTASIS Volume: 13 Page(s): 68 - 68
06/01/2015 Authors: Meeks S
An Immunodominant B Cell Epitope is Present on the C1 Domain of FVIII
HAEMOPHILIA Volume: 21 Page(s): E260 - E261
05/01/2015 Authors: Batsuli G; Healey J; Baldwin W; Parker E; Lollar P; Meeks S
Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
J Thromb Haemost Volume: 13 Page(s): 72 - 81
01/01/2015 Authors: Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
The 1.7 X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces.
PLoS One Volume: 10 Page(s): e0122447
01/01/2015 Authors: Brison CM; Mullen SM; Wuerth ME; Podolsky K; Cook M; Herman JA; Walter JD; Meeks SL; Spiegel PC
The Diversity of Anti-Factor VIII B-Cell Epitopes in Hemophilia a Patients with Inhibitors
BLOOD Volume: 124
12/06/2014 Authors: Robinson MA; Cox C; Baldwin WH; Zakas P; Meeks SL
Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain Injury
BLOOD Volume: 124
12/06/2014 Authors: Doshi BS; Meeks SL; Hendrickson JE; Reisner A; Leong T; Winkler AM; Meyer E
The 1.7 Angstrom X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces
Volume: 124
12/06/2014 Authors: Brison CM; Mullen SM; Podolsky K; Meeks SL; Spiegel PC
Decreasing the Humoral Response to Factor VIII By Targeted Deletion of Factor VIII - Specific B Cells
Volume: 124
12/06/2014 Authors: Markovitz RC; Healey JF; Baldwin WH; Parker ET; Meeks SL; Lollar P
Anti-Factor VIII C1 Domain Antibodies Are Present in the Plasmas of Patients with Hemophilia and Inhibitors
Volume: 124
12/06/2014 Authors: Batsuli G; Cox C; Healey JF; Lollar P; Meeks SL
Beyond the Bethesda Assay-Towards Individualized Interpretation of Inhibitor Patients' FVIII Brand Specific Profiles
Volume: 124
12/06/2014 Authors: Livnat T; Dunn A; Azar-Avivi S; Cox C; Avishai E; Meeks SL; Kenet G
Toward optimal therapy for inhibitors in hemophilia.
Hematology Am Soc Hematol Educ Program Volume: 2014 Page(s): 364 - 371
12/05/2014 Authors: Kempton CL; Meeks SL
Toward optimal therapy for inhibitors in hemophilia.
Blood Volume: 124 Page(s): 3365 - 3372
11/27/2014 Authors: Kempton CL; Meeks SL
Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
Haemophilia Volume: 20 Page(s): e344 - e346
07/01/2014 Authors: Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL
Predictors of response to combination therapy with recombinant Factor VIIa and Factor VIII in patients with hemophilia A and high titer inhibitors
HAEMOPHILIA Volume: 20 Page(s): 42 - 42
05/01/2014 Authors: Dunn AL; Nguyen B; Baldwin WH; Kenet G; Meeks SL
High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.
Blood Volume: 123 Page(s): 2732 - 2739
04/24/2014 Authors: Nguyen P-CT; Lewis KB; Ettinger RA; Schuman JT; Lin JC; Healey JF; Meeks SL; Lollar P; Pratt KP
Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.
Blood Volume: 122 Page(s): 4270 - 4278
12/19/2013 Authors: Walter JD; Werther RA; Brison CM; Cragerud RK; Healey JF; Meeks SL; Lollar P; Spiegel PC
Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factorVIII by hydrogen-deuterium exchange mass spectrometry.
J Thromb Haemost Volume: 11 Page(s): 2128 - 2136
12/01/2013 Authors: Sevy AM; Healey JF; Deng W; Spiegel PC; Meeks SL; Li R
B-Cell Epitopes Within The A2 and C2 Domains Of Coagulant Factor VIII Refined By Orthologous Protein Antigenicity
Volume: 122
11/15/2013 Authors: Zakas PM; Vanijcharoenkarn K; Markovitz R; Meeks SL; Doering CB
An epitope-dependent increase in clearance of antigen-antibody complexes may increase the pathogenicity of a subset of anti-C2 factor fVIII antibodies in hemophilia A
JOURNAL OF THROMBOSIS AND HAEMOSTASIS Volume: 11 Page(s): 259 - 260
07/01/2013 Authors: Meeks SL; Cox CL; Parker ET
Late immune tolerance induction in haemophilia A patients.
Haemophilia Volume: 19 Page(s): 445 - 448
05/01/2013 Authors: Meeks SL; Chapman RL; Kempton C; Dunn AL
One Year Follow-Up of Changes in Epitope Specificity, Inhibitor Titer, and Antibody Titer in a Patient with Severe Hemophilia A after Rituximab
HAEMOPHILIA Volume: 19 Page(s): 466 - 466
05/01/2013 Authors: Dunn A; Chapman R; Cox C; Meeks S
Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.
J Biol Chem Volume: 288 Page(s): 9905 - 9914
04/05/2013 Authors: Walter JD; Werther RA; Polozova MS; Pohlman J; Healey JF; Meeks SL; Lollar P; Spiegel PC
The diversity of the immune response to the A2 domain of human factor VIII.
Blood Volume: 121 Page(s): 2785 - 2795
04/04/2013 Authors: Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
Development of factor VIII inhibitors in two patients with moderate haemophilia A.
Haemophilia Volume: 19 Page(s): e55 - e57
01/01/2013 Authors: Paschal RD; Meeks SL; Neff AT
Medical radiation exposure in children with bleeding disorders: an institutional experience.
Haemophilia Volume: 18 Page(s): 888 - 891
11/01/2012 Authors: Crawford CC; Meeks SL; Dunn AL
A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
Blood Volume: 120 Page(s): 2512 - 2520
09/20/2012 Authors: Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
ROLE OF RACE/ETHNICITY ON IMMUNE TOLERANCE INDUCTION AND INHIBITOR RELAPSE IN CHILDREN WITH HEMOPHILIA A
PEDIATRIC BLOOD & CANCER Volume: 58 Page(s): 1032 - 1032
07/01/2012 Authors: Batsuli G; Chapman R; Cox C; Dunn A; Meeks S
Changes in Epitope Specificity, Inhibitor Titer, and Antibody Titer in a Patient with Severe Hemophilia A Undergoing Immune Tolerance Therapy with Rituximab and Recombinant Factor VIII
AMERICAN JOURNAL OF HEMATOLOGY Volume: 87 Page(s): S165 - S165
05/01/2012 Authors: Chapman R; Cox C; Dunn A; Meeks S
Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
PLoS One Volume: 7 Page(s): e48172
01/01/2012 Authors: Doshi BS; Gangadharan B; Doering CB; Meeks SL
The Structural and Functional Diversity of the Humoral Immune Response to the A2 Domain of Human Factor VIII
Volume: 118 Page(s): 977 - 978
11/18/2011 Authors: Markovitz R; Lollar JPS; Healey JF; Parker ET; Meeks S
High-Resolution Mapping of B-Cell Epitopes on the Factor VIII C2 Domain Using Surface Plasmon Resonance
Volume: 118 Page(s): 95 - 95
11/18/2011 Authors: Phuong-Cac N; Lewis KB; Schuman JT; Meeks SL; Healey JF; Lollar P; Pratt KP
Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies
Volume: 118 Page(s): 990 - 991
11/18/2011 Authors: Negrier C; Meeks SL; Oldenburg J; Martinowitz U; Bordet J-C; Poetzsch B; Al Dieri R; Dargaud Y; Hemker C; Eckmann C
Factor VIII Structure, Not Activity, Is the Primary Determinant of Immunogenicity in Hemophilia A and Combined Hemophilia A/Von Willebrand Disease Mice
Volume: 118 Page(s): 535 - 536
11/18/2011 Authors: Meeks SL; Cox C; Healey JF; Parker ET; Gangadharan B; Barrow RT; Lollar JPS
Factor VIII Supplementation Improves Recombinant VIIa Initiated Thrombin Generation in Hemophilia A Inhibitor Patient Plasmas
Volume: 118 Page(s): 17 - 17
11/18/2011 Authors: Doshi B; Cox C; Gangadharan B; Doering CB; Meeks SL
Factor VIII supplementation improves hemophilia a thrombin generation in the presence of FVIII inhibitors and recombinant factor VIIa
JOURNAL OF THROMBOSIS AND HAEMOSTASIS Volume: 9 Page(s): 686 - 687
07/01/2011 Authors: Meeks SL; Gangadharan B; Doering CB
Medical radiation exposure in children with bleeding disorders
HAEMOPHILIA Volume: 17 Page(s): 565 - 565
05/01/2011 Authors: Crawford CC; Meeks SL; Dunn AL
Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.
Blood Volume: 117 Page(s): 3190 - 3198
03/17/2011 Authors: Summers RJ; Meeks SL; Healey JF; Brown HC; Parker ET; Kempton CL; Doering CB; Lollar P
Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
Haemophilia Volume: 17 Page(s): 155 - 156
01/01/2011 Authors: Kempton CL; Meeks SL; Donald Harvey R; Abshire TC
N1922S Mutation In the Factor VIII A3 Domain Produces a Rate-Limiting, Domain-Specific Folding Defect Leading to Hyposecretion of a Functional Protein.
Volume: 116 Page(s): 910 - 910
11/19/2010 Authors: Summers RJ; Meeks SL; Healey JF; Brown HC; Parker ET; Doering C; Kempton CL; Lollar JPS
Cooperative Interaction Between Classical and Non-Classical Factor VIIII C2 Domain Antibody Epitopes
Volume: 114 Page(s): 95 - 96
11/20/2009 Authors: Antun AG; Meeks SL; Healey JF; Parker ET; Lollar P
Proteolytically Inactivatable Factor VIII is Less Immunogenic than Factor VIII in a Murine Hemophilia A Model
Volume: 114 Page(s): 17 - 17
11/20/2009 Authors: Meeks S; Parker ET; Dunn AL; Healey JF; Lollar P
A Subset of High Titer Acquired Hemophilia Patients May Benefit from Treatment with High Dose Factor VIII
Volume: 114 Page(s): 1349 - 1349
11/20/2009 Authors: Meeks S; Healey JF; Parker ET; Lollar P
Immune tolerance in patients with hemophilia A and longstanding inhibitors
Volume: 7 Page(s): 518 - 519
07/01/2009 Authors: Dunn AL; Meeks SL; Chapman RL; Kempton CL
Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.
J Thromb Haemost Volume: 7 Page(s): 658 - 664
04/01/2009 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
B-Cell Epitope Mapping of Monoclonal Anti-Factor VIII C2 Domain Inhibitors: Identification of Amino Acids That Contribute Significant Antigen-Antibody Binding Affinity.
Volume: 112 Page(s): 441 - 441
11/16/2008 Authors: Lin JC; Schuman JT; Meeks SL; Healey JF; Thompson AR; Pratt KP
Non-Classical Anti-Factor VIII C2 Domain Antibodies Are Pathogenic in a Murine in Vivo Bleeding Model.
Volume: 112 Page(s): 706 - 707
11/16/2008 Authors: Meeks S; Healey JF; Parker ET; Barrow RT; Lollar JP
Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment.
Haemophilia Volume: 14 Page(s): 1159 - 1163
11/01/2008 Authors: Meeks SL; Abshire TC
Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.
Blood Volume: 112 Page(s): 1151 - 1153
08/15/2008 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Blood Volume: 110 Page(s): 4234 - 4242
12/15/2007 Authors: Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
Non-classical anti-factor VIIIC2 domain inhibitors are present in the plasmas of most factor VIII inhibitor patients
Volume: 110 Page(s): 242A - 242A
11/16/2007 Authors: Meeks SL; Healey JF; Barrow RT; Parker ET; Lollar P
Enhanced anticoagulant activity of factor VIII inhibitors due to positive cooperativity between two classes of anti-factor VIII C2 antibodies
Volume: 110 Page(s): 241A - 241A
11/16/2007 Authors: Meeks SL; Healey JF; Barrow RT; Parker ET; Lollar P
Identification of three non-overlapping epitopes in the C2 domain of factor VIII.
Volume: 108 Page(s): 300A - 300A
11/16/2006 Authors: Meeks S; Healey JF; Lollar JPS
Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates.
Curr Opin Hematol Volume: 13 Page(s): 457 - 461
11/01/2006 Authors: Meeks SL; Josephson CD
Extravasation of hyperalimentation into the liver parenchyma from a peripherally inserted central catheter.
J Pediatr Surg Volume: 38 Page(s): E8
04/01/2003 Authors: Meeks SL; Ciambotti JM; Rodgers BM; Gordon PV
Duration of atrial fibrillation and imminence of stroke: the Framingham study.
Stroke Volume: 14 Page(s): 664 - 667
01/01/1983 Authors: Wolf PA; Kannel WB; McGee DL; Meeks SL; Bharucha NE; McNamara PM